Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data

Abstract

Background:

In 1967, concerns about the carcinogenic potential of psychedelics arose after chromosomal damage in human leukocytes following in vitro lysergic acid (LSD) exposure was reported in the literature. Worries were further heightened by subsequent reports of leukemia and other cancers in LSD users. Additional investigations of psychedelics’ effects on chromosomes were published over the next decade, with the bulking suggesting these concerns were unfounded. However, the relationship between psychedelics and cancer has been explored only minimally from an epidemiological perspective.

Aims:

To determine whether associations exist between psychedelic use and either lifetime cancer or hematologic cancer diagnoses.

Methods:

We analyzed data from adult participants in the 2015–2019 administrations of the National Survey on Drug Use and Health for associations between lifetime use of psychedelics and lifetime diagnosis of either any cancer or hematologic cancer.

Results:

We identified no associations between lifetime psychedelic use and either lifetime cancer diagnosis or hematologic cancer diagnosis. Sub-analyses of lifetime lysergamide, phenethylamine, and tryptamine use also revealed no associations with lifetime cancer or hematologic cancer diagnosis.

Conclusions:

While laboratory studies and case reports from the 1960s and 1970s generated concerns about psychedelics’ carcinogenic potential, this analysis of recent epidemiological data does not support an association between psychedelic use and development of cancer in general or hematologic cancer. Important study limitations to consider include a lack of information about psychedelic dosage, number of lifetime psychedelic exposures, and the temporal relationship between psychedelic use and cancer diagnosis.

Keywords

Psychedelic cancer leukemia lymphoma psilocybin LSD MDMA

Get full access to this article

View all access options for this article.

References

Alcover

Thompson

(2020) Patterns of mean age at drug use initiation among adolescents and emerging adults, 2004-2017. JAMA Pediatr 174: 725–727.

Berliner

Distenfeld

(1972) Hodgkin’s disease in a married couple. JAMA 221: 703–704.

Bloom

Neel

Choi

, et al. (1970) Chromosome aberrations among the Yanomamma Indians. Proc Natl Acad Sci USA 66: 920–927.

Bronson

Stroop

Zimmer

, et al. (2017) Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009. Washington, DC. Available at: https://bjs.ojp.gov/content/pub/pdf/dudaspji0709.pdf (accessed 26 June 2022).

Chagnon

Le Quesne

Cook

(1971) Yanomamo hallucinogens: Anthropological, botanical, and chemical findings. Curr Anthropol 12: 72–74.

Cohen

Hirschhorn

Frosch

(1967) In vivo and in vitro chromosomal damage induced by LSD-25. N Engl J Med 277: 1043–1049.

Cohen

Hirschhorn

Frosch

(1969) Cytogenetic effects of tranquilizing drugs in vivo and in vitro. JAMA 207: 2425–2426.

Cohen

Hirschhorn

Verbo

, et al. (1968) The effect of LSD-25 on the chromosomes of children exposed in utero. Pediatr Res 2: 486–492.

Cohen

Marinello

Back

(1967) Chromosomal damage in human leukocytes induced by lysergic acid diethylamide. Science (New York, N.Y.) 155: 1417–1419.

10.

Cohen

Shiloh

(1977) Genetic toxicology of lysergic acid diethylamide (LSD-25). Mutat Res 47(3–4): 183–209.

11.

Corey

Andrews

McLeod

, et al. (1970) Chromosome studies on patients (in vivo) and cells (in vitro) treated with lysergic acid diethylamide. N Engl J Med 282: 939–943.

12.

DeWit

Adlaf

Offord

, et al. (2000) Age at First Alcohol Use: A Risk Factor for the Development of Alcohol Disorders Am J Psychiatry 157: 745–750.

13.

Dishotsky

Loughman

Mogar

, et al. (1971) LSD and genetic damage. Science (New York, N.Y.) 172: 431–440.

14.

Dorrance

Janiger

Teplitz

(1970) In vivo effects of illicit hallucinogens on human lymphocyte chromosomes. JAMA 212: 1488–1491.

15.

Dorrance

Janiger

Teplitz

(1975) Effect of peyote on human chromosomes. Cytogenetic study of the Huichol Indians of Northern Mexico. JAMA 234: 299–302.

16.

Eberle

Leuner

(1970) Chromosomendefekte bei Psilocybin-Patienten. Humangenetik 9: 281–285.

17.

Egozcue

Irwin

(1969) Effect of LSD-25 on mitotic and meiotic chromosomes of mice and monkeys. Humangenetik 8: 86–93.

18.

Egozcue

Irwin

Maruffo

(1968) Chromosomal damage in LSD Users. JAMA 204: 214–218.

19.

Ganne-Carrié

Nahon

(2019) Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 70: 284–293.

20.

Garson

Robson

(1969) Studies in a patient with acute leukaemia after lysergide treatment. Br Med J 2: 800–802.

21.

Geber

(1967) Congenital malformations induced by mescaline, lysergic acid diethylamide, and bromolysergic acid in the hamster. Science (New York, N.Y.) 158: 265–267.

22.

Ghasemiesfe

Barrow

Leonard

, et al. (2019) Association between marijuana use and risk of cancer: A systematic review and meta-analysis. JAMA Netw Open 2: e1916318.

23.

Goh

Bauman

(1978) Lysergic acid diethylamide and acute leukemia. J Am Med Women’s Assoc (1972) 33: 419–422.

24.

Grof

(1980) The effect of LSD on chromosomes, genetic mutation, fetal development and malignancy. In: Grof S (ed.) LSD Psychotherapy, 1st edn. Pomona, CA: Hunter House, pp.318–347.

25.

Grossbard

Rosen

McGilvray

, et al. (1968) Acute leukemia with Ph1-like chromosome in an LSD user. JAMA. 205: 791–793.

26.

Harrison

Martin

Enev

, et al. (2007) Comparing drug testing and self-report of drug use among youths and young adults in the general population. Rockville, MD: Substance Abuse and Mental Health Services Administration. Available at: https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.182.9980&rep=rep1&type=pdf (accessed 26 June 2022).

27.

Haverkos

(1996) The epidemiologic scope of Kaposi’s sarcoma. Oncology (Williston Park, N.Y.) 10(Suppl): 8–9.

28.

Hecht

(2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3: 733–744.

29.

Houston

(1969) Review of the evidence and qualifications regarding the effects of hallucinogenic drugs on chromosomes and embryos. Am J Psychiatry 126: 251–254.

30.

Hulvat

(2020) Cancer incidence and trends. Surg Clin North Am 100: 469–481.

31.

Hungerford

Taylor

Shagass

, et al. (1968) Cytogenetic effects of LSD 25 therapy in man. JAMA 206: 2287–2291.

32.

Iqbal

Nguyen

Syed-Abdul

, et al. (2015) Is long-term use of benzodiazepine a risk for cancer? Medicine 94: e483.

33.

Irwin

Egozcue

(1967) Chromosomal abnormalities in leukocytes from LSD-25 users. Science (New York, N.Y.) 157: 313–314.

34.

Jacobson

Berlin

(1972) Possible reproductive detriment in LSD users. JAMA 222: 1367–1373.

35.

Jarvik

Yen

Dahlberg

, et al. (1974) Chromosome examinations after medically administered lysergic acid diethylamide and dextroamphetamine. Dis Nerv Syst 35: 399–407.

36.

Judd

Brandkamp

McGlothlin

(1969) Comparison of the chromosomal patterns obtained from groups of continued users, former users, and nonusers of LSD-25. Am J Psychiatry 126: 626–635.

37.

Jurič

Zandona

Lovaković

, et al. (2021) Cytotoxic, genotoxic, and oxidative stress-related effects of lysergic acid diethylamide (LSD) and phencyclidine (PCP) in the human neuroblastoma SH-SY5Y cell line. Arch Ind Hyg Toxicol 72: 333–342.

38.

Kao

C-H

Sun

L-M

Liang

J-A

, et al. (2012) Relationship of zolpidem and cancer risk: A Taiwanese population-based cohort study. Mayo Clinic Proc 87: 430–436.

39.

Kato

Tominaga

Terao

(1989) An epidemiological study on marital status and cancer incidence. Jpn J Cancer Res 80: 306–311.

40.

Kato

Jarvik

(1969) LSD-25 and genetic damage. Dis Nerv Syst 30: 42–46.

41.

Kim

Scialli

(2011) Thalidomide: The tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122: 1–6.

42.

Koretzky

(2007) The legacy of the Philadelphia chromosome. J Clin Invest 117: 2030–2032.

43.

Larsen

Myklebust

Babigumira

, et al. (2020) Education, income and risk of cancer: Results from a Norwegian registry-based study. Acta Oncol (Stockholm, Sweden) 59: 1300–1307.

44.

Leukemia & Lymphoma Center (2021) Facts and Statistics Overview. Available at: https://www.lls.org/facts-and-statistics/facts-and-statistics-overview (accessed: 30 May 2022).

45.

Levick

(1971) Testicular choriocarcinoma in LSD users: Coincidence or cause? JAMA 217: 475–476.

46.

Lin

(1998) Genetic toxicology of abused drugs: A brief review. Mutagenesis 13: 557–565.

47.

Loughman

Sargent

Israelstam

(1967) Leukocytes of humans exposed to lysergic acid diethylamide: Lack of chromosomal damage. Science (New York, N.Y.) 158: 508–510.

48.

Madera Tribune (1968) Evidence LSD causes cancer, deformities. 20 February, P. 3. Available at: https://cdnc.ucr.edu/?a=d&d=MT19680220.2.30&e=-------en--20--1--txt-txIN--------1.

49.

Muneer

(1978) Effects of LSD on human chromosomes. Mutat Res/Fundam Mol Mech Mutagen 51: 403–410.

50.

National Cancer Institute (2021) Cancer Stat Facts: Cancer of Any Site, Surveillance, epidemiology and end results program. Available at: https://seer.cancer.gov/statfacts/html/all.html (accessed 28 October 2021).

51.

Nelson

Levine

Marks

, et al. (1997) Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin’s lymphoma. Br J Cancer 76: 1532–1537.

52.

Song

I-A

(2020) Chronic opioid use and risk of cancer in patients with chronic noncancer pain: A nationwide historical cohort study. Cancer Epidemiol Biomark Prevent 29: 1962–1967.

53.

Oram

(2016) Prohibited or regulated? LSD psychotherapy and the United States Food and Drug Administration. Hist Psychiatry 27: 290–306.

54.

RAND Corporation (2018) 2015 Department of Defense Health Related Behaviors Survey (HRBS). Santa Monica, CA. Available at: https://www.health.mil/Reference-Center/Reports/2018/06/21/2015-HRBS-Final-Report.

55.

Rehm

Soerjomataram

Ferreira-Borges

, et al. (2019) Does alcohol use affect cancer risk? Curr Nutr Rep 8: 222–229.

56.

Reiff

Richman

Nemeroff

, et al. (2020) Psychedelics and Psychedelic-Assisted Psychotherapy. Am J Psychiatry 177: 391–410.

57.

Rendon

(1974) The effect of psychotomimetic drugs upon human chromosomes in tissue culture. La Cellule 70: 331, 333–358.

58.

Ribes

Clèries

Esteban

, et al. (2008) The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 49: 233–242.

59.

Riddel

Hales

(2018) Predicting cancer-prevention behavior: Disentangling the effects of risk aversion and risk perceptions. Risk Anal 38: 2161–2177.

60.

Robbins

Engels

Pfeiffer

, et al. (2015) Age at cancer diagnosis for blacks compared with whites in the United States. J Natl Cancer Inst 107: dju489.

61.

Robinson

Chitham

Greenwood

, et al. (1974) Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. Br J Psychiatry 125: 238–244.

62.

Ross

(2018) Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry (Abingdon, England) 30(4): 317–330.

63.

Schlag

Aday

Salam

, et al. (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol 36: 258–272.

64.

Sexton

Nichols

Hendricks

(2020) Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front Psychiatry 10: 896.

65.

Shiels

Engels

(2017) Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 12: 6–11.

66.

Siegel

Miller

Jemal

(2017) Cancer Statistics, 2017. CA A Cancer J for Clin 67: 7–30.

67.

Simonsson

Hendricks

Carhart-Harris

, et al. (2021) Association between lifetime classic psychedelic use and hypertension in the past year. Hypertension 77: 1510–1516.

68.

Simonsson

Sexton

Hendricks

(2021) Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol 35: 447–452.

69.

Sohn

Boggs

(1974) Klinefelter’s syndrome, LSD usage and acute lymphoblastic leukemia. Clin Genet 6: 20–22.

70.

Stenchever

Jarvis

(1970) Lysergic acid diethylamide (LSD). Effect on human chromosomes in vivo. Am J Obstetr Gynecol 106: 485–488.

71.

Substance Abuse and Mental Health Services Administration (2020a) 2019 National Survey on Drug Use and Health (NSDUH): Methodological Resource Book, Section 8, Data collection final report. Rockville, MD. Available at: https://www.samhsa.gov/data/report/nsduh-2019-data-collection-final-report (accessed 26 June 2022).

72.

Substance Abuse and Mental Health Services Administration (2020b) 2019 National Survey on Drug Use and Health (NSDUH): Methodological Summary and Definitions. Rockville, MD. Available at: https://www.samhsa.gov/data/sites/default/files/reports/rpt29395/2019NSDUHMethod (accessed 26 June 2022).

73.

Substance Abuse and Mental Health Services Administration (2020c) 2019 National Survey on Drug Use and Health (NSDUH) methodological resource book: Section 2: Sample design report. Rockville, MD. Available at: https://www.samhsa.gov/data/report/nsduh-2019-sample-design-report (accessed 26 June 2022).

74.

Substance Abuse and Mental Health Services Administration (2020d) 2019 National Survey on Drug Use and Health Public Use File Codebook. Rockville, MD. Available at: https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-2019/NSDUH-2019-datasets/NSDUH-2019-DS0001/NSDUH-2019-DS0001-info/NSDUH-2019-DS0001-info-codebook.pdf (accessed 26 June 2022).

75.

Substance Abuse and Mental Health Services Administration (2021) 2020 National Survey on Drug Use and Health Public Use File Codebook. Rockville, MD. Available at: https://www.datafiles.samhsa.gov/sites/default/files/field-uploads-protected/studies/NSDUH-2020/NSDUH-2020-datasets/NSDUH-2020-DS0001/NSDUH-2020-DS0001-info/NSDUH-2020-DS0001-info-codebook.pdf (accessed 26 June 2022).

76.

Sullivan

(1967) Studies conflict on LSD damage to chromosomes. New York Times, 27 October.

77.

Tjio

J-H

Pahnke

Kurland

(1969) LSD and chromosomes: A controlled experiment. JAMA 210: 849–856.

78.

Van Went

(1978) Mutagenicity testing of 3 hallucinogens: LSD, psilocybin and delta 9-THC, using the micronucleus test. Experientia 34: 324–325.

79.

White

Holman

Boehm

, et al. (2014) Age and cancer risk: A potentially modifiable relationship. Am J Prevent Med 46(Suppl 1): S7–S15.

80.

Yockey

Vidourek

King

(2020) Trends in LSD use among US adults: 2015–2018. Drug Alcohol Depend 212: 108071.

81.

Zahnd

James

Jenkins

, et al. (2018) Rural-urban differences in cancer incidence and trends in the United States. Cancer Epidemiol Biomarkers Prev 27: 1265–1274.

82.

Zhao

Okoro

, et al. (2018) Health insurance status and clinical cancer screenings among U.S. adults. Am J Prev Med 54: e11–e19.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB